Page 4 - hypertension_newsletter
P. 4

REFLECTIONS
                                                                                                                   Hypertension
     Hypertension Global Newsletter #10 2026


     The 2025 multi-society guideline looks to reverse poor BP
     control rates and mitigate the public health burden of CVD.                                                   Hypertension
     By transitioning to the contemporary PREVENT calculator for
     more equitable and precise risk stratification, emphasizing the
     use of SPCs to improve patient adherence, and establishing a
     rigorous baseline BP target, this document modernizes everyday
     prescribing practices.
                                                                         CLICK HERE
                                                                         LISTEN TO A PODCAST IN WHICH
                                                                         AUTHOR DANIEL W. JONES, MD AND
                                                                         CLYDE W. YANCY MD, MACC DISCUSS
              CLICK HERE                                                 THE 2025 AHA/ACC HIGH BLOOD
              FOR THE LINK TO FULL ARTICLE                               PRESSURE GUIDELINE (13:58)



     Single-pill combination therapy for the management of hypertension: A scientific
     statement from the American Heart Association.
     King JB, et al. Hypertension. 2026 Mar;83(3):e00258.

     Hypertension remains a leading cause of global CV morbidity, with population-level BP control rates stagnating around 25% in the
     United States. A primary driver of this is the traditional prescribing paradigm. Historically, clinicians have relied on a “stepped-care”
     approach, initiating a single medication and gradually titrating it over time. However, because most patients ultimately require
     two to four different medications to achieve strict contemporary targets (typically <130/80 mmHg), this approach often leads to
     therapeutic inertia and a high daily pill burden, causing a decrease in patient adherence.

     This 2026 scientific statement from the American Heart Association (AHA) reviewed the current clinical evidence, randomised
     controlled trials (RCTs), and real-world implementation data surrounding the pharmacologic management of hypertension.
     The objective was to provide expert guidance on transitioning clinical practice away from traditional monotherapy toward the
     widespread adoption of SPCs, while also identifying remaining barriers and knowledge gaps hindering their broader use.

                  Starting with single-pill combination medications compared with stepped care






























                                                                                                SPCM, single-pill combination
                                                                                                medication.


          TABLE OF CONTENTS
   1   2   3   4   5   6   7   8   9